In contrast to the expression profile observed in normal tissue, aberrant COUP-TFII expression has been frequently reported in different types of human tumors including breast cancer[25, 26], pancreatic adenocarcinoma[27], colorectal cancer[28], ovarian cancer[29–31] and prostate carcinomas[16]. This evidence concerns the gene NR2F2 and ovarian cancer.